Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

• Status: Recruiting
• Trial end date: 2032-12-01

Summary

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)

• Phase: Phase 3

Details

• Lead Sponsor: BeiGene
• Treatments: Obinutuzumab; Venetoclax; Zanubrutinib